| Inhibition of MDR1 overcomes resistance to brentuximab vedotin in Hodgkin lymphoma R Chen, AF Herrera, J Hou, L Chen, J Wu, Y Guo, TW Synold, VN Ngo, ... Clinical Cancer Research 26 (5), 1034-1044, 2020 | 53 | 2020 |
| Ubiquitin-specific protease 22 is critical to in vivo angiogenesis, growth and metastasis of non-small cell lung cancer K Zhang, L Yang, J Wang, T Sun, Y Guo, R Nelson, TR Tong, R Pangeni, ... Cell Communication and Signaling 17, 1-17, 2019 | 45 | 2019 |
| Eribulin synergistically increases anti-tumor activity of an mTOR inhibitor by inhibiting pAKT/pS6K/pS6 in triple negative breast cancer W Wen, E Marcinkowski, D Luyimbazi, T Luu, Q Xing, J Yan, Y Wang, ... Cells 8 (9), 1010, 2019 | 24 | 2019 |
| MAP2K1 mutations in advanced colorectal cancer predicts a poor response to anti-EGFR therapy and to vertical targeting of the MAPK pathway J Chuang, C Wang, Y Guo, V Valenzuela, JW Marwan, Fakih colorectal cancer 15 (Issue 2), 2020 | 14 | 2020 |
| Cetuximab-triptolide conjugate suppresses the growth of EGFR-overexpressing lung cancers through targeting RNA polymerase II K Zhang, Y Ma, Y Guo, T Sun, J Wu, RP Pangeni, M Lin, W Li, D Horne, ... Molecular Therapy-Oncolytics 18, 304-316, 2020 | 14 | 2020 |
| Increasing Antitumor Activity of JAK Inhibitor by Simultaneous Blocking Multiple Survival Signaling Pathways in Human Ovarian Cancer YJH Wen W, Han ES, Dellinger TH, Wu J, Guo Y, Buettner R, Horne DA, Jove R Translational Oncology, 2019 | 12 | 2019 |
